Heparin-induced thrombocytopenia: A general review

Journal of Infusion Nursing

Volumn 30, Issue 4, 2007, Pages 232-240

  Swanson, Joseph M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGATROBAN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; QUINIDINE; RIFAMPICIN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBUS;

ANTICOAGULANTS; DRUG MONITORING; FACTOR XA; HEPARIN; HIRUDINS; HUMANS; NURSING ASSESSMENT; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PLATELET ACTIVATION; PLATELET COUNT; POLYSACCHARIDES; RECOMBINANT PROTEINS; RISK FACTORS; THROMBIN; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 34547663295     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000281533.04808.54     Document Type: Review

References (69)

1. Rice L. Evolving management strategies for heparin-induced thrombocytopenia. Semin Hematol. 2005;42:S15-21.
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
3. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
4. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
5. Newman PM, Chong BH. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
6. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
7. Warner MN, Pavord S, Moore JC, Warkentin TE, Hayward CP, Kelton JG. Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders. J Lab Clin Med. 1999;133:129-133.
8. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost. 1998;80:326-331.
9. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97:3300-3302.
10. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S-337S.
11. Almeida JI, Coats R, Liem TK, Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1998;27:309-314; discussion 315-316.
12. Silver D, Kapsch DN, Tsoi EK. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg. 1983;198:301-306.
13. Spinler SA. Managing heparin-induced thrombocytopenia: Preventing life- and limb-threatening thrombosis. Am J Health Syst Pharm. 2003;60(Suppl 5):S2-4.
14. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:638-648.
15. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol. 2001;185:148-152.
16. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood. 2003;101:2955-2959.
17. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
18. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: A retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol. 2001;108:1134-1140.
19. Francis JL, Palmer GJ III, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003;75:17-22.
20. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol. 2002;118:1137-1142.
21. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006;26:1438-1445.
22. Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest. 2006;130:681-687.
23. Gettings EM, Brush KA, Van Cott EM, Hurford WE. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: An observational retrospective case-control study. Crit Care. 2006;10:R161.
24. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated anti-platelet antibodies. Arch Intern Med. 1989;149:2285-2287.
25. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518-2524.
26. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med. 2002;126:1415-1423.
27. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
28. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37-42.
29. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210-215.
30. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med. 2003;348:1067-1069.
31. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med. 2005;45:417-419.
32. Spinler SA. New concepts in heparin-induced thrombocytopenia: Diagnosis and management. J Thromb Thrombolysis. 2006;21:17-21.
33. Jackson MR, Neilson WJ, Lary M, Baay P, Web K, Clagett GP. Delayed-onset heparin-induced thrombocytopenia and thrombosis after intraoperative heparin anticoagulation: Four case reports. Vasc Endovascular Surg. 2006;40:67-70.
34. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: A retrospective analysis of 408 patients. Thromb Haemost. 2005;94:132-135.
35. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
36. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101:3049-3051.
37. Hach-Wunderle V, Kainer K, Salzmann G, Muller-Berghaus G, Potzsch B. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg. 1997;173:117-119.
38. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
39. Warkentin TE. Heparin-induced thrombocytopenia: A clinicopathologic syndrome. Thromb Haemost. 1999;82:439-447.
40. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest. 1993;104:1436-1440.
41. Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition. Ann Thorac Surg. 1992;53:787-791.
42. Walls JT, Boley TM, Curtis JJ, Silver D. Heparin induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery. ASAIO J. 1992;38:M574-576.
43. Bartholomew JR. The incidence and clinical features of heparininduced thrombocytopenia. Semin Hematol. 2005;42:S3-8.
44. White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: Including six cases of heparin-induced skin necrosis. Ann Surg. 1979;190:595-608.
45. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest. 2005;127:1857-1861.
46. Popov D, Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism: Acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis. 1997;29:449-452.
47. Ansell JE, Clark WP Jr, Compton CC. Fatal reactions associated with intravenous heparin. Drug Intell Clin Pharm. 1986;20:74-75.
48. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: Sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003;497-519.
49. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
50. Warkentin TE. Heparin-induced thrombocytopenia: Diagnosis and management. Circulation. 2004;110:e454-458.
51. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000;10(Suppl 1):35-45.
52. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
53. Vun CM, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res. 1996;81:525-532.
54. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999;100:587-593.
55. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation. 1999;99:73-80.
56. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia: Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3:2428-2436.
57. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
58. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
59. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129:1407-1416.
60. Angiomax™ (bivalirudin) [package insert]. Parsippany, NJ: The Medicines Company, 2004.
61. Nand S. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol. 1993;43:310-311.
62. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006;26:461-468.
63. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:1384-1385.
64. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother. 2006;40:1383-1387.
65. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006;26:452-460.
66. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: Systematic review and meta-analysis of randomised controlled trials. BMJ. 1998;316:969-975.
67. Refludan® [lepirudin (rDNA)] [package insert]. Montville, NJ: Berlex, 2004.
68. Argatroban [package insert]. Bellaire, TX: GlaxoSmithKline, 2005.
69. Arixtra® (fondaparinux) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005.